Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359249 | PMC |
http://dx.doi.org/10.4103/ijo.IJO_99_22 | DOI Listing |
NPJ Digit Med
December 2024
Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA.
Where adopted, Autonomous artificial Intelligence (AI) for Diabetic Retinal Disease (DRD) resolves longstanding racial, ethnic, and socioeconomic disparities, but AI adoption bias persists. This preregistered trial determined sensitivity and specificity of a previously FDA authorized AI, improved to compensate for lower contrast and smaller imaged area of a widely adopted, lower cost, handheld fundus camera (RetinaVue700, Baxter Healthcare, Deerfield, IL) to identify DRD in participants with diabetes without known DRD, in primary care. In 626 participants (1252 eyes) 50.
View Article and Find Full Text PDFComput Biol Med
January 2025
Department of Ophthalmology, University Clinical Center. Prof. Kornel Gibiński, Medical University of Silesia, Katowice, Poland; Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
BMJ Open
May 2024
NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK
Int J Ophthalmol
January 2024
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Eye Diseases, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai 200085, China.
Purpose: To compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD).
Methods: This was a randomized, multicenter, non-inferiority study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!